Shire PLC (SHP) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Shire PLC (LON:SHP) have earned a consensus rating of “Buy” from the twenty-two ratings firms that are currently covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is GBX 4,886.67 ($63.85).
SHP has been the topic of a number of recent analyst reports. Deutsche Bank reiterated a “buy” rating on shares of Shire in a research report on Friday, October 12th. Barclays increased their target price on Shire from GBX 3,900 ($50.96) to GBX 4,700 ($61.41) and gave the company an “equal weight” rating in a research report on Friday, August 10th. Berenberg Bank lowered Shire to a “hold” rating and increased their target price for the company from GBX 4,500 ($58.80) to GBX 5,000 ($65.33) in a research report on Thursday, September 6th. Shore Capital restated a “hold” rating on shares of Shire in a report on Monday, July 2nd. Finally, Liberum Capital restated a “hold” rating on shares of Shire in a report on Tuesday, July 10th.
Shares of LON:SHP traded up GBX 63.50 ($0.83) during midday trading on Thursday, reaching GBX 4,528 ($59.17). 913,355 shares of the company’s stock traded hands, compared to its average volume of 3,140,000. Shire has a 1 year low of GBX 2,940.50 ($38.42) and a 1 year high of GBX 5,021 ($65.61).
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Further Reading: How is an ETF different from a mutual fund?
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.